- DYAX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $44.1 million.
- DYAX has traded 240,455 shares today.
- DYAX is down 3% today.
- DYAX was up 5.9% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in DYAX with the Ticky from Trade-Ideas. See the FREE profile for DYAX NOW at Trade-Ideas More details on DYAX: Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. Currently there are 7 analysts that rate Dyax a buy, no analysts rate it a sell, and 1 rates it a hold. The average volume for Dyax has been 2.0 million shares per day over the past 30 days. Dyax has a market cap of $3.5 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.43 and a short float of 4.2% with 4.59 days to cover. Shares are up 72.5% year-to-date as of the close of trading on Wednesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.